Andrew Mammen, M.D., Ph.D.

Investigator

Muscle Disease Unit

NIAMS

Building 50, Room 1146
50 South Drive
Bethesda, MD 20814

301-594-6667

mammenal@mail.nih.gov

Research Topics

Dr. Andrew Mammen and researchers at the Muscle Disease Unit (MDU) study myositis, a family of autoimmune diseases that affect skeletal muscle and, in many cases, other organs such as the skin, lungs, and joints. These diseases include dermatomyositis, polymyositis, immune-mediated necrotizing myopathy, and inclusion body myositis. Members of the MDU direct their efforts towards understanding the classification, natural history, and pathologic mechanisms of these diseases with the goal of improving diagnostic and treatment strategies. Current projects include the following:

  • Defining the different subtypes of autoimmune muscle disease based on muscle histology, autoantibodies, and other biomarkers.
  • Elucidating the role of myositis autoantibodies in the pathogenesis of myositis.
  • Developing animal models of myositis that are relevant to the human diseases.
  • Understanding how environmental exposures, including medications such as statins and cancer immunotherapies, can trigger autoimmune muscle disease.
  • Using novel therapeutic strategies to treat myositis patients at the NIH Clinical Center.

Biography

After obtaining his M.D. and Ph.D. at Johns Hopkins, Dr. Mammen completed his neurology residency and neuromuscular fellowship at the same institution. He co-founded the Johns Hopkins Myositis Center in 2007. He and his colleagues discovered a novel form of autoimmune myopathy associated with statin use and autoantibodies recognizing HMG-CoA reductase, the pharmacologic target of statins. In 2014, Dr. Mammen moved to the NIH, where he is an Investigator and Leader of the Muscle Disease Unit. In addition to seeing myositis patients at the NIH Clinical Center, he maintains an appointment as Adjunct Professor of Neurology and Medicine at Hopkins, where he continues to see patients at the Myositis Center.

Selected Publications

  1. Lloyd TE, Pinal-Fernandez I, Michelle EH, Christopher-Stine L, Pak K, Sacktor N, Mammen AL. Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients. Neurology. 2017;88(15):1454-1460.

  2. Mammen AL. Statin-Associated Autoimmune Myopathy. N Engl J Med. 2016;374(7):664-9.

  3. Mammen AL, Tiniakou E. Intravenous Immune Globulin for Statin-Triggered Autoimmune Myopathy. N Engl J Med. 2015;373(17):1680-2.

  4. Yeker RM, Pinal-Fernandez I, Kishi T, Pak K, Targoff IN, Miller FW, Rider LG, Mammen AL, Childhood Myositis Heterogeneity Collaborative Study Group.. Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis. Ann Rheum Dis. 2018;77(5):714-719.

  5. Mammen AL, Rajan A, Pak K, Lehky T, Casciola-Rosen L, Donahue RN, Lepone LM, Zekeridou A, Pittock SJ, Hassan R, Schlom J, Gulley JL. Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1. Ann Rheum Dis. 2018.


This page was last updated on September 25th, 2018